[Use of topical pharyngeal anaesthesia in esophagogastroduodenoscopy in unsedated XXXX ].

@entity1 @entity3303
AIM: Evaluation of effect on tolerance of topical pharyngeal anaesthesia with a @entity3303 spray in esophagogastroduodenoscopy (EGD), and possible secondary factors that could influence it. METHODS: A prospective, experimental, randomized, open-label study was performed in our Endoscopy Unit during January 2010. Outpatients (109) were recruited prospectively and randomized between two groups: L group (52), who received @entity3303 (50 mg Xilonibsa 10% before examination), and C group (57) who did not. Sedated @entity1 were not included in this study. Age, sex, Mallampati index (lower I and II; higher III and IV), endoscopist, complications and score (0-100; visual analogue scale) was recorded after each EGD. RESULTS: There were no statistical differences between the two groups as regards @entity1 tolerance. However in stratified analysis the application of @entity3303 modified the results in two out of the six endoscopists and improved the scores in @entity1 with a higher Mallampati Index (L group 61.8    24 and C group 47.7    32). Significant differences were also observed in the scores on @entity1 tolerance between the endoscopist (operator dependent factor), regardless of the use of topical pharyngeal anaesthesia or not. CONCLUSIONS: The systematic use of @entity3303 in EGD is safe but does not improve the tolerance in all outpatients. Only the Mallampati index has been identified as a prognosis factor of good response to @entity3303 administration. Additionally the nursing-endoscopist could be a very important factor in the scores obtained independently of @entity3303 .
